• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of direct data communications with Review/Policy Divisions within CDER (Office of Generic Drugs (OGD), Office of New Drug Quality Assessment (ONDQA), Office of Biotechnology Products (OBP), Office of Compliance (OC), Office of New Drugs (OND), CDER/Immediate Office (IO)) and Office of the Commissioner within the month)

Dictionary: The Office of Testing and Research (OTR) is tracking the number of research summaries, findings, and/or results OTR provides to CDER and other Agency customers.


These measures has been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A75
Nov 2009N/A7
Dec 2009N/A2
Jan 2010N/A7
Feb 2010N/A11
Mar 2010N/A16
Apr 2010N/A11
May 2010N/A32
Jun 2010N/A37
Jul 2010N/A29
Aug 2010N/A33
Sep 2010N/A46

FY 2010 Total: 306

Number of Interim and Final Technical Reports sent to Review/Policy Divisions CDER (OGD, ONDQA, OBP, OC, OND, CDER/IO) and Office of the Commissioner within the month

Dictionary: OTR is tracking the number of technical reports OTR provides to CDER and other Agency customers.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A3
Nov 2009N/A1
Dec 2009N/A5
Jan 2010N/A5
Feb 2010N/A3
Mar 2010N/A7
Apr 2010N/A7
May 2010N/A6
Jun 2010N/A4
Jul 2010N/A8
Aug 2010N/A6
Sep 2010N/A7

FY 2010 Total: 62

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.